USD
$0.00
(0.00%
)At Close (As of Nov 6, 2025)
$108.55M
Market Cap
-
P/E Ratio
-3.78
EPS
$13.50
52 Week High
$2.27
52 Week Low
CONSUMER DEFENSIVE
Sector
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$21M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $1.6M |
| Capital Expenditures | $15K |
| Change In Receivables | - |
| Change In Inventory | -$31K |
| Profit Loss | - |
| Cashflow From Investment | $6.3M |
| Cashflow From Financing | -$1.5M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$39M |
Sector: CONSUMER DEFENSIVE
Industry: PACKAGED FOODS
Clene Inc. is an innovative clinical-stage pharmaceutical firm headquartered in Salt Lake City, Utah, specializing in the development of clean-surface nanotechnology (CSN) therapies intended to address neurodegenerative diseases and other critical health conditions. With a strong emphasis on rigorous clinical trials, Clene is focused on achieving regulatory approvals for its advanced product pipeline, which positions the company as a potential leader in transforming treatment options within the biopharmaceutical sector. Given its robust scientific foundation and strategic vision, Clene presents an attractive opportunity for institutional investors seeking growth in the healthcare market.